Eton Pharmaceuticals (ETON) Retained Earnings (2017 - 2025)

Eton Pharmaceuticals (ETON) has 9 years of Retained Earnings data on file, last reported at -$112.5 million in Q4 2025.

• For the quarter ending Q4 2025, Retained Earnings fell 4.26% year-over-year to -$112.5 million; the trailing twelve-month figure through Dec 2025 stood at -$112.5 million (down 4.26% YoY), and the FY2025 full-year result was -$112.5 million, down 4.26% from the prior year.
• Retained Earnings eased to -$112.5 million in Q4 2025, from $137.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $137.1 million in Q3 2025 to a low of -$112.5 million in Q4 2025.
• A 5-year average of -$90.5 million and a median of -$103.6 million in 2022 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings decreased 18.85% in 2021 and soared 227.76% in 2025, its largest moves.
• Tracing ETON's Retained Earnings over 5 years: stood at -$94.1 million in 2021, then fell by 9.59% to -$103.1 million in 2022, then dropped by 0.91% to -$104.1 million in 2023, then retreated by 3.67% to -$107.9 million in 2024, then slipped by 4.26% to -$112.5 million in 2025.
• Business Quant data shows ETON's Retained Earnings at -$112.5 million in Q4 2025, $137.1 million in Q3 2025, and -$112.0 million in Q2 2025.